drugset / Trial / NCT02468375

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

NCT02468375

Phase 4 Completed 434 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the treatment satisfaction after switching to mirabegron in patient with Overactive Bladder(OAB) who were unsatisfied with efficacy of antimuscarinic therapy or adverse event. Patient will take the mirabegron 50mg/day for 12 weeks, and the satisfation of the therapy will be measured with Treatment Satisfaction Questionnaire(TSQ), Global Response Assessment(GRA), OAB-q short form, OAB Symptom Score and Willingness to continue Questions.

Timeline

Start
2015-06
Primary completion
2017-10
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 50 mg

Indications